Observational Study in Type 2 Diabetes Treated by an Intensive Insulin Treatment (ICT) Containing Once Daily Levemir® (Insulin Detemir)

Novo Nordisk A/S2,289 enrolled

Overview

This study is conducted in Europe. The aim of this observational study is to gain practical experience with once-daily Levemir administration in type 2 diabetes patients who were previously treated with Insulatard®, Humulin® N (NPH insulins) as basal insulin as part of their ICT under normal clinical practice conditions in Hungary.

Study Type

OBSERVATIONAL

Enrollment

2,289

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

insulin detemirDRUG

observational study - dose and frequency to be prescribed by the physician as a result of standard clinical practice.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Type 2 diabetic subjects on intensive insulin treatment (ICT) * Eligibility for once daily insulin detemir administration * Informed consent obtained before any observation-related activities Exclusion Criteria: * Known or suspected allergy to insulin detemir * Subjects previously enrolled in the observation * Women who are pregnant, breast feeding or have the intention of becoming pregnant within 6 months.

Locations (1)

Unnamed facility

Budapest, Hungary

Outcomes

Primary Outcomes

Efficacy (HbA1c)

Time frame: 24 weeks

Secondary Outcomes

Body weight

Time frame: 24 weeks

Hypoglycaemia frequency

Time frame: 24 weeks

FBG variability

Time frame: 24 weeks

Insulin dose change

Time frame: 24 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.